Comparison of the efficacy and safety of ultrasonic cycloplasty vs valve implantation and anti-VEGF for the treatment of fundus disease-related neovascular glaucoma
Authors: Fan Fang-Fang ,   The Affiliated Xuzhou Municipal Hospital of Xuzhou Medical University, Xuzhou 221000, Jiangsu Province, China; Department of Ophthalmology, Xuzhou First People&#x2019;s Hospital, Xuzhou 221000, Jiangsu Province, China, Liu Dan-Dan , Xu Teng-Yu , Wang Rui-Xue , Chen Xiao-Ya , Li Su-Yan ,   The Affiliated Xuzhou Municipal Hospital of Xuzhou Medical University, Xuzhou 221000, Jiangsu Province, China; Department of Ophthalmology, Xuzhou First People&#x2019;s Hospital, Xuzhou 221000, Jiangsu Province, China,   The Affiliated Xuzhou Municipal Hospital of Xuzhou Medical University, Xuzhou 221000, Jiangsu Province, China; Department of Ophthalmology, Xuzhou First People&#x2019;s Hospital, Xuzhou 221000, Jiangsu Province, China,   The Affiliated Xuzhou Municipal Hospital of Xuzhou Medical University, Xuzhou 221000, Jiangsu Province, China; Department of Ophthalmology, Xuzhou First People&#x2019;s Hospital, Xuzhou 221000, Jiangsu Province, China,   The Affiliated Xuzhou Municipal Hospital of Xuzhou Medical University, Xuzhou 221000, Jiangsu Province, China; Department of Ophthalmology, Xuzhou First People&#x2019;s Hospital, Xuzhou 221000, Jiangsu Province, China; Eye Disease Prevention and Treatment Institute of Xuzhou, Xuzhou 221000, Jiangsu Province, China,   The Affiliated Xuzhou Municipal Hospital of Xuzhou Medical University, Xuzhou 221000, Jiangsu Province, China; Department of Ophthalmology, Xuzhou First People&#x2019;s Hospital, Xuzhou 221000, Jiangsu Province, China; Eye Disease Prevention and Treatment Institute of Xuzhou, Xuzhou 221000, Jiangsu Province, China
Published: May 2023

AIM: To compare the clinical efficacy and safety of ultrasonic cycloplasty (UCP) vs Ahmed glaucoma drainage valve implantation (ADV) in addition to intravitreal anti-vascular endothelial growth factor (VEGF) for treatment of fundus disease-related neovascular glaucoma (NVG).
METHODS: A total of 43 patients (45 eyes) with NVG secondary to fundus diseases underwent anti-VEGF combined with UCP or ADV from August 2020 to March 2022 were enrolled in this retrospective cohort study. Of them, 14 patients (15 eyes) were treated with both UCP and anti-VEGF as the UCP group and 29 patients (30 eyes) treated with both ADV and anti-VEGF as the ADV group. The success of the treatment was defined as intraocular pressure (IOP) between 11-20 mm Hg with or without using IOP-lowering drugs. IOP measurement, IOP lowering drugs at baseline and follow-ups period and complications were recorded.
RESULTS: The average age was 63.03±9.95 and 52.27±12.89y in ADV and UCP groups, respectively (P=1.947). The fundus pathology included proliferative diabetic retinopathy in 42 eyes and retinal vein occlusion in 3 eyes. All eyes in both groups achieved successful treatment at 3mo. While the success rate was 90.0% (27/30) in the ADV group and 86.7% (13/15) in the UCP group at the last follow-up of 6mo (P>0.05). IOP was significantly lower with reduction of drug use than the baseline in both groups (both P<0.05). And the ADV group needed fewer anti-glaucoma drops than the UCP group from 1d to 3mo. The comfort scores of patients in the ADV group were significantly lower than those in the UCP group in the first week after the operation (P<0.05).
CONCLUSION: UCP is an alternative to the ADV with the same efficacy but non-invasive for the treatment of NVG.